SCHEMBL1993818

SCHEMBL1993818

CN(C)CC1CCn2c(cc3ccccc32)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.45
HTR2C P28335 5/20 0.45
SIGMAR1 Q99720 6/20 0.44
PRKCB P05771 4/20 0.41
PRKCE Q02156 4/20 0.40
PRKD3 O94806 2/20 0.40
PRKCG P05129 2/20 0.40
PRKCA P17252 2/20 0.40
PRKCH P24723 2/20 0.40
PRKCQ Q04759 2/20 0.40
PRKCD Q05655 2/20 0.40
PRKD1 Q15139 2/20 0.40
PHKG2 P15735 1/20 0.40
PRKCI P41743 1/20 0.40
PHKA2 P46019 1/20 0.40
PHKA1 P46020 1/20 0.40
GSK3B P49841 1/20 0.40
PRKCZ Q05513 1/20 0.40
PHKG1 Q16816 1/20 0.40
PHKB Q93100 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8655904 0.81 PRKCE (0.51) HTR2AHTR2CSIGMAR1PRKCBPRKCE
SCHEMBL1991214 0.81 HTR2A (0.48) HTR2AHTR2CSIGMAR1PRKCBPRKCE
SCHEMBL8318760 0.81 HTR2A (0.48) HTR2AHTR2CSIGMAR1PRKCBPRKCE
SCHEMBL8324461 0.81 HTR2A (0.48) HTR2AHTR2CSIGMAR1PRKCBPRKCE
SCHEMBL8451898 0.78 HTR2A (0.42) HTR2AHTR2CSIGMAR1PRKCEMYLK
SCHEMBL8451901 0.78 HTR2A (0.42) HTR2AHTR2CSIGMAR1PRKCEMYLK
SCHEMBL8449854 0.77 SIGMAR1 (0.49) HTR2AHTR2CSIGMAR1PRKCEMYLK
SCHEMBL8448934 0.76 HTR2A (0.40) HTR2AHTR2CSIGMAR1PRKCEMYLK
SCHEMBL6015848 0.76 SIGMAR1 (0.44) HTR2AHTR2CSIGMAR1PRKCEMYLK
SCHEMBL1999141 0.76 HTR2A (0.40) HTR2AHTR2CSIGMAR1PRKCEMYLK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO HTR2A 1080/4885HTR2C 648/4885SIGMAR1 512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.